欧洲膀胱疾病市场 – 行业趋势和 2029 年预测

欧洲膀胱疾病市场分析与洞察 

膀胱疾病是一组会影响人类日常生活的疾病。最常见的膀胱疾病包括膀胱炎（膀胱感染并引起炎症）。尿失禁（失去膀胱控制）、间质性膀胱炎（膀胱疼痛和频繁、紧迫排尿）和膀胱过度活动症（膀胱挤压尿液的一种情况）。膀胱疾病会影响生活质量并导致其他健康问题。健康变化和问题（包括神经系统和生活方式因素）可能导致或加剧男性和女性的 UI。

最常见的膀胱疾病是膀胱过度活动症和尿路感染。这些问题与神经系统有关。神经将信息从大脑传递到膀胱，指示肌肉收缩或释放。

预计欧洲膀胱疾病市场将在 2022 年至 2029 年的预测期内增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 10.7%，预计将从 2021 年的 23.3269 亿美元增至 2029 年的 52.26 亿美元。

欧洲膀胱疾病市场的市场定义

Bladder related disorders include cystitis - inflammation of the bladder, often from an infection, urinary incontinence - loss of bladder control, overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.

Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures.

Anticholinergic medications are the first-line of pharmacotherapy in overactive bladder (OAB) syndrome. OAB is a clinical symptom characterized by urgency of desire to urine pass, which is difficult to defer, generally frequency to pass urine more than eight times per day are consider into OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle that reduce the bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.

Europe Bladder Disorders Market Dynamics

Drivers

• STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.

Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum revenue.

• GROWING GERIATRIC POPULATION

Aging is a strong risk factor that can associate with bladder-related disorders. Aging prompts neurologic, anatomic, and biochemical changes in bladder function, which can dispose to the development of OAB and Overactive bladder is the most common problem among the geriatric population. Aging population is suffering from various bladder-associated problems and disorders due to which they are the predominant users of chronic health management services and solutions.

According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, treatment guidelines specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with Neurologic disorders such as dementia, and in this age group, OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.

• RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

Various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.

• COMBINATION OF DIFFERENT TARGET THERAPIES

Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

• SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.

Bladder disorder management now emphasizes assisting patients with various alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.

Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes.

• RISING DISEASE MANAGEMENT PROGRAMS

People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems coupled with increasing healthcare expenditures has encouraged better healthcare plans.

Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.

Restraints/Challenges

However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.

This Bladder Disorders Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe Bladder Disorders Market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Post COVID-19 Impact on Europe Bladder Disorders Market

COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market

Recent Development

• In February, AbbVie announced the U.S. FDA approval for the BOTOX® for treating detrusor (bladder muscle) over activity associated with a neurologic condition in pediatric patients 5 years of age. "BOTOX® is the first neurotoxin authorized to treat neurogenic detrusor over activity in children whose condition cannot be successfully treated by anticholinergic therapy." This approval will increase the revenue of the company

Europe Bladder Disorders Market Scope

Europe bladder disorders market is segmented into type, treatment type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

• Cystitis
• Urinary Incontinence
• Overactive Bladder
• Interstitial Cystitis
• Bladder Cancer

On the basis of type, the Europe bladder disorders market is segmented into cystitis, urinary incontinence, overactive bladder, interstitial cystitis, and bladder cancer

Treatment type

• Surgery
• Medications
• Others

On the basis of product, the Europe bladder disorders market is segmented into surgery, medication, and others

End user

• Hospital
• Clinics
• Ambulatory Surgery centers
• Others

On the basis of end users, the Europe bladder disorders market is segmented into hospitals, clinics, ambulatory surgery centers, and others

Distribution Channel

• Direct
• Retail

On the basis of distribution channel, the Europe bladder disorders market is segmented into direct and retail

Europe Bladder Disorders Market Regional Analysis/Insights  

Europe bladder disorders market is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above.

Countries covered in this market are Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe.

Germany dominates the Europe bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and growing R&D investments and the launch of novel therapies are boosting the market

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Europe brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Bladder Disorders Market Share Analysis

欧洲膀胱疾病市场竞争格局提供了有关竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、亚太地区业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上数据点仅与公司对欧洲膀胱疾病市场的关注有关。

欧洲膀胱疾病市场的一些主要参与者包括美敦力、Laborie、波士顿科学公司、辉瑞公司、安斯泰来制药公司、KYORIN 制药有限公司（KYORIN Holdings, Inc. 的子公司）、百时美施贵宝公司、强生服务公司、Axonics, Inc.、默克公司、Viatris Inc.、Blue Wind Medical、Gaylord Chemical Company, LLC、Coloplast Corp、艾伯维公司、太阳制药工业有限公司、Zydus Group 和 Urovant Sciences 等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、欧洲与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。

SKU-69071